Xenon Pharmaceuticals paused enrollment in its major depressive disorder and bipolar disorder trials for azetukalner after neuropsychiatric adverse events emerged that were not seen in earlier studies. The company said current participants will remain in the studies and data are expected in early 2027, while the pause reflects a safety review during expansion.